Posted inCardiology Clinical Updates news
Systolic Blood Pressure as a Key Modifier of Survival Benefit from Microaxial Flow Pump Therapy in Infarct-Related Cardiogenic Shock: Insights from the DanGer Shock Trial
This post hoc analysis of the DanGer Shock trial reveals that low systolic blood pressure at treatment initiation markedly enhances survival benefit from microaxial flow pump support in infarct-related cardiogenic shock.